Defunct Company
Total Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
89
NCT03094169
AVID100 in Advanced Epithelial Carcinomas
Phase: Phase 1/2
Role: Lead Sponsor
Start: Feb 1, 2017
Completion: Jan 30, 2021
NCT03834662
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
Phase: Phase 1
Role: Collaborator
Start: Jan 7, 2019
Completion: Feb 19, 2020
NCT03895112
MPN-RC 118 AVID200 in Myelofibrosis
Start: Feb 15, 2019
Completion: May 16, 2022